119114
Luciferase Inhibitor II
The Luciferase Inhibitor II, also referenced under CAS 10205-56-8, controls the biological activity of Luciferase.
别名:
Luciferase Inhibitor II, 4-(1,3-Benzothiazol-2-yl)-N,N-dimethylaniline
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H14N2S
化学文摘社编号:
分子量:
254.35
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.28
SMILES string
[s]1c2c(nc1c3ccc(cc3)N(C)C)cccc2
InChI
1S/C15H14N2S/c1-17(2)12-9-7-11(8-10-12)15-16-13-5-3-4-6-14(13)18-15/h3-10H,1-2H3
InChI key
HYKGLCSXVAAXNC-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
pale green
solubility
DMSO: 0.5 mg/mL, ethanol: 3 mg/mL
shipped in
ambient
Quality Level
General description
A 2-arylbenzothiazole compound that acts as an inhibitor against the ATP-dependent Photinus pyralis (lucPpy) and Photuris pennsylvanica (lucPpe) luciferase activity (IC50 = 0.2 and 0.32 µM, respectively, with 10 µM ATP, 10 µM luciferin, and 10 nM respective enzyme). Unlike Luciferase Inhibitor I (Cat. No. 119113), Luciferase Inhibitor II is competitive with respect to luciferin and exhibits reduced potency against lucPpe-based commercial luciferase-luciferin formulations with high luciferin concentration (IC50 = 10 µM against Promega′s Kinase-Glo; ineffective against Kinase-Glo Plus and Kinase-Glo Max; at a 3-fold formulation dilution and 6.77 µM ATP).
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Auld, D.S., et al. 2009. J. Med. Chem.52, 1450.
Auld, D.S., et al. 2008. J. Med. Chem.51, 2372.
Auld, D.S., et al. 2008. J. Med. Chem.51, 2372.
Legal Information
Marketed by Promega Corp. under the registered trademarks.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Alexandre Berthier et al.
STAR protocols, 2(3), 100658-100658 (2021-07-22)
Here, we describe an optimized protocol to identify specific nuclear receptor ligands. First, to rule out any compound interference with luciferase activity per se, we describe an in vitro assay assessing potential inhibition or activation of luciferase enzymatic activity. Second
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持